Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Eloralintide

A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes

Eli Lilly · Phase 2 · Active, not recruiting · Enrollment 200

NCT07215559

ArmPopulationDoseWeeksEstimandWeight change
Macupatide (Macupatide + Eloralintide Placebo)Obesity + T2Dn/rn/rn/rn/r
Eloralintide (Elorlintide + Macupatide Placebo)Obesity + T2Dn/rn/rn/rn/r
Macupatide + EloralintideObesity + T2Dn/rn/rn/rn/r
Placebo (Macupatide Placebo + Elorlintide Placebo)Obesity + T2Dn/rn/rn/rn/r